Arcus Biosciences (RCUS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.72
- EPS estimate
- −$0.89
- EPS surprise
- +19.21%
- Revenue surprise
- +86.52%
- Revenue
- $41.0M
- Revenue estimate
- $22.0M
- Reported
- Aug 5, 2026
Arcus Biosciences reported Q2 2026 results on August 5, 2026. It posted a loss of $0.72 per share, narrower than the $0.89 loss expected, a 19.21% beat. Revenue was $41.0 million, 86.52% above the $22.0 million consensus. Compared with Q2 2025, when EPS was $0.00 on revenue of $160.0 million, the result moved back to a loss and revenue fell about 74%.
Most quarters in the table are losses of roughly $0.90 to $1.14 per share on revenue of $17 million to $48 million. Three quarters stand out. Q4 2021 brought $354.5 million and a profit of $3.71 per share, Q1 2024 $145.0 million and a near break-even loss of $0.05, and Q2 2025 $160.0 million at break-even. Annual losses were $3.72 per share in 2022, $4.15 in 2023 and $3.10 in 2024. The table has no Q3 2025 row, so no 2025 total can be given. The first half of 2026 shows a combined loss of $1.74, against $1.14 a year earlier. Arcus beat the EPS estimate in 14 of the 20 quarters shown.
Q3 results came between November 2 and November 8 from 2021 to 2024. That points to early November 2026 for the next report.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | −$0.89 | −$0.72 | +19.21% | $41.0M | SEC |
| Q1 2026 | May 5, 2026 | −$0.88 | −$1.02 | −15.88% | $17.0M | SEC |
| Q4 2025 | Feb 25, 2026 | −$1.11 | −$0.89 | +19.55% | $33.0M | SEC |
| Q2 2025 | Aug 6, 2025 | −$1.13 | $0.00 | +100.00% | $160.0M | SEC |
| Q1 2025 | May 6, 2025 | −$1.03 | −$1.14 | −10.57% | $28.0M | SEC |
| Q4 2024 | Feb 25, 2025 | −$1.25 | −$1.03 | +17.51% | $36.0M | SEC |
| Q3 2024 | Nov 6, 2024 | −$1.06 | −$1.00 | +5.33% | $48.0M | SEC |
| Q2 2024 | Aug 8, 2024 | −$1.12 | −$1.02 | +8.52% | $39.0M | SEC |
| Q1 2024 | May 8, 2024 | −$1.01 | −$0.05 | +95.05% | $145.0M | SEC |
| Q4 2023 | Feb 21, 2024 | −$1.02 | −$1.08 | −5.41% | $31.0M | SEC |
| Q3 2023 | Nov 7, 2023 | −$1.13 | −$0.94 | +16.77% | $32.0M | SEC |
| Q2 2023 | Aug 7, 2023 | −$1.10 | −$1.04 | +5.31% | $29.0M | SEC |
| Q1 2023 | May 9, 2023 | −$1.16 | −$1.09 | +6.33% | $25.0M | SEC |
| Q4 2022 | Feb 28, 2023 | −$1.14 | −$0.93 | +18.38% | $34.0M | SEC |
| Q3 2022 | Nov 2, 2022 | −$1.04 | −$0.90 | +13.33% | $33.6M | SEC |
| Q2 2022 | Aug 3, 2022 | −$0.94 | −$0.93 | +1.19% | $26.8M | SEC |
| Q1 2022 | May 9, 2022 | −$0.85 | −$0.96 | −12.36% | $18.0M | SEC |
| Q4 2021 | Feb 23, 2022 | −$1.09 | $3.71 | +439.18% | $354.5M | SEC |
| Q3 2021 | Nov 8, 2021 | −$1.06 | −$1.11 | −5.00% | $9.5M | SEC |
| Q2 2021 | Aug 5, 2021 | −$0.87 | −$1.09 | −24.71% | $9.5M | SEC |
Quarterly revenue
Frequently asked questions
When did Arcus Biosciences (RCUS) last report earnings?
Arcus Biosciences last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did RCUS beat earnings estimates?
Yes. Arcus Biosciences reported EPS of −$0.72 for Q2 2026 against a −$0.89 estimate — a 19.21% beat.
How much revenue did RCUS report last quarter?
Arcus Biosciences reported $41.0M in revenue for Q2 2026, against a consensus estimate of $22.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.